Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)

被引:35
作者
Lenders, Nele [1 ,2 ,3 ]
McCormack, Ann [1 ,2 ]
机构
[1] Garvan Inst Med Res, Sydney, NSW, Australia
[2] Univ New South Wales, St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
关键词
Pituitary carcinomas; Non-functioning pituitary adenomas; Aggressive pituitary tumours; Metastases; Temozolomide; OF-THE-LITERATURE; RECEPTOR RADIONUCLIDE THERAPY; SILENT CORTICOTROPH ADENOMAS; LONG-TERM SURVIVAL; TEMOZOLOMIDE TREATMENT; RADIATION-THERAPY; CUSHING DISEASE; P53; EXPRESSION; CELL-CARCINOMA; TUMOR CELLS;
D O I
10.1007/s11102-017-0857-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.
引用
收藏
页码:217 / 229
页数:13
相关论文
共 122 条
[1]   Oncogene-induced senescence in pituitary adenomas and carcinomas [J].
Alexandraki, Krystallenia I. ;
Khan, Mohammed Munayem ;
Chahal, Harvinder S. ;
Dalantaeva, Nadezhda S. ;
Trivellin, Giampaolo ;
Berney, Dan M. ;
Caron, Philippe ;
Popovic, Vera ;
Pfeifer, Marija ;
Jordan, Suzanne ;
Korbonits, Marta ;
Grossman, Ashley B. .
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2012, 11 (03) :297-307
[2]   Invasive Pituitary Adenomas: Significance of Proliferation Parameters [J].
Amar A.P. ;
Hinton D.R. ;
Krieger M.D. ;
Weiss M.H. .
Pituitary, 1999, 2 (2) :117-122
[3]   Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature [J].
Annamalai, A. K. ;
Dean, A. F. ;
Kandasamy, N. ;
Kovacs, K. ;
Burton, H. ;
Halsall, D. J. ;
Shaw, A. S. ;
Antoun, N. M. ;
Cheow, H. K. ;
Kirollos, R. W. ;
Pickard, J. D. ;
Simpson, H. L. ;
Jefferies, S. J. ;
Burnet, N. G. ;
Gurnell, M. .
PITUITARY, 2012, 15 (03) :276-287
[4]  
[Anonymous], 2004, WHO CLASSIFICATION T
[5]   Pituitary adenoma growth: A model for cellular senescence and cytokine action [J].
Arzt, Eduardo ;
Chesnokova, Vera ;
Stalla, Gueter K. ;
Melmed, Shlomo .
CELL CYCLE, 2009, 8 (05) :677-678
[6]   First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment [J].
S. Baldari ;
F. Ferraù ;
C. Alafaci ;
A. Herberg ;
F. Granata ;
V. Militano ;
F. M. Salpietro ;
F. Trimarchi ;
S. Cannavò .
Pituitary, 2012, 15 (Suppl 1) :S57-S60
[7]   GONADOTROPIC PITUITARY CARCINOMA - CASE-REPORT [J].
BEAUCHESNE, P ;
TROUILLAS, J ;
BARRAL, F ;
BRUNON, J .
NEUROSURGERY, 1995, 37 (04) :810-815
[8]   Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside [J].
Ben-Shlomo, Anat ;
Cooper, Odelia .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (04) :301-305
[9]   Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide [J].
Bengtsson, Daniel ;
Schroder, Henrik Daa ;
Andersen, Marianne ;
Maiter, Dominique ;
Berinder, Katarina ;
Rasmussen, Ulla Feldt ;
Rasmussen, Ase Krogh ;
Johannsson, Gudmundur ;
Hoybye, Charlotte ;
van der Lely, Aart Jan ;
Petersson, Maria ;
Ragnarsson, Oskar ;
Burman, Pia .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04) :1689-1698
[10]   A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry [J].
Brown, Rebecca L. ;
Muzzafar, Tariq ;
Wollman, Robert ;
Weiss, Roy E. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (05) :639-643